USRE36150E - Deformable-elastic intraocular lens - Google Patents

Deformable-elastic intraocular lens Download PDF

Info

Publication number
USRE36150E
USRE36150E US08/538,757 US53875795A USRE36150E US RE36150 E USRE36150 E US RE36150E US 53875795 A US53875795 A US 53875795A US RE36150 E USRE36150 E US RE36150E
Authority
US
United States
Prior art keywords
lens body
methacrylate
lens
acrylate
deformable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/538,757
Inventor
Amitava Gupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
AMO Puerto Rico Inc
Original Assignee
AMO Puerto Rico Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22274275&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE36150(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US08/538,757 priority Critical patent/USRE36150E/en
Application filed by AMO Puerto Rico Inc filed Critical AMO Puerto Rico Inc
Assigned to ALLERGAN reassignment ALLERGAN ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALLERGAN, INC.
Publication of USRE36150E publication Critical patent/USRE36150E/en
Application granted granted Critical
Assigned to BANK OF AMERICA, N.A. reassignment BANK OF AMERICA, N.A. SECURITY AGREEMENT Assignors: ADVANCED MEDICAL OPTICS, INC., AMO HOLDINGS, LLC
Assigned to BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT reassignment BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT SECURITY AGREEMENT Assignors: ADVANCED MEDICAL OPTICS, INC.
Assigned to ADVANCED MEDICAL OPTICS, INC. reassignment ADVANCED MEDICAL OPTICS, INC. RELEASE OF SECURITY INTEREST AT REEL/FRAME NO. 16386/0001 Assignors: BANK OF AMERICA, N.A.
Assigned to AMO HOLDINGS, INC. (FORMERLY KNOWN AS AMO HOLDINGS, LLC), ADVANCED MEDICAL OPTICS, INC. reassignment AMO HOLDINGS, INC. (FORMERLY KNOWN AS AMO HOLDINGS, LLC) RELEASE OF SECURITY INTEREST AT REEL/FRAME NO. 13203/0039 Assignors: BANK OF AMERICA, N.A.
Anticipated expiration legal-status Critical
Assigned to AMO PUERTO RICO MANUFACTURING, INC. reassignment AMO PUERTO RICO MANUFACTURING, INC. ASSET PURCHASE AGREEMENT Assignors: AMO PUERTO RICO, INC.
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/16Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/14Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16Intraocular lenses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/14Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16Intraocular lenses
    • A61F2/1613Intraocular lenses having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus
    • A61F2/1616Pseudo-accommodative, e.g. multifocal or enabling monovision
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/16Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea

Definitions

  • the present invention relates generally to improvements in intraocular lenses (IOLs) designed for surgical implantation into the eye, for example, as a replacement for a cataractous or injured natural lens. More specifically, the invention relates to improvements in deformable IOLs which can be folded or rolled to a relatively low profile size to fit into the eye through a relatively small incision, and then within the eye naturally return to an internal nondeformed shape with predetermined optical properties.
  • IOLs intraocular lenses
  • IOLs are well known in the art for implantation into the eye as a replacement for a natural crystalline lens which has been surgically removed typically due to opacification, commonly referred to as a cataract condition.
  • Such IOLs have been formed from a small disk of transparent glass or plastic material having appropriately shaped lens surfaces to achieve a desired set of optical properties.
  • the IOL is implanted directly into the eye, typically after removal of the natural crystalline lens, via an incision formed in ocular tissue such as the scalera outside the normal line of sight.
  • Many IOLs are designed for implantation into the so-called posterior chamber of the eye behind the iris and pupil, whereas other IOLs are adapted for placement into the anterior chamber in front of the iris and pupil.
  • support structures are attached to or formed integrally with a central lens body or optic and project outwardly therefrom to contact eye tissue at the periphery of the posterior or anterior chamber, thereby retaining the lens body or optic in generally centered relation with the line of sight passing through the pupil.
  • PMMA polymethylmethacrylate
  • PMMA polymethylmethacrylate
  • PMMA comprises a plastic matrix which, when formed into the shape of a lens, possesses high rigidity and cannot be deformed by folding, rolling, compression, etc.
  • the use of PMMA lenses requires a relatively large incision in the ocular tissue sufficient to accommodate the entire diametric size of the lens body; which is typically six millimeters or larger, together with the accompanying lens supports structures.
  • the resilient lens support structures such as polypropylene loops or haptics are commonly used and advantageously may be folded over the lens body during insertion, such resilient haptics are anchored into the periphery of the hard plastic lens body and thus tend to spring back to their initial unfolded shape with a rapid snap like action during IOL implantation, resulting in undesired trauma to sensitive eye tissues.
  • an IOL including a deformable transparent lens body which may be folded or rolled into a reduced profile size may fit through a relatively small incision in ocular tissue and after insertion and release within the eye return to its original size and shape by virtue of its natural resilience.
  • the use of a smaller incision would beneficially result in a safer overall surgical procedure requiring fewer stitches and reduced likelihood of postoperative complications such as infections.
  • a smaller incision would reduce the incidence of postoperative astigmatism and substantially reduce rehabilitation time.
  • IOLs with deformable lens bodies may reduce the potential for complications secondary to contact or rubbing against delicate uveal tissues. Also, deformable IOLs may decrease the potential for pigmentary dispersion or pigmentary glaucoma. Finally, it is anticipated that the formable IOLs will provide an added margin of safety for patients with blood dyscarsias, coagulopalthies and hematologic matogrant disease as well as those patients being given anti-coagulant therapy.
  • deformable IOLs formed of silicones and hydrogels have been proposed for implantation.
  • Fyodorov reported on chemical testing of a silicone IOL (Fyodorov, S. W. et al "Initial Clinical Testing of a Silicone Intraocular Lens” Interzonal Scientific/Practical Conference of Ophthalmologists of Western and Eastern Siberia and the Far East, Conference Proceedings 4: 22-24, 1983, Vladivostock).
  • Mazzacco and Davidson presented initial data on the implantation of silicone IOLs with 6 mm optical zones through 3 mm incisions (Mazzacco, T. R. and Davidson, V. A.
  • silicones and hydrogels have several well documented deficiencies which hinder their use as IOL materials.
  • silicones cause complement activation leading to the production of C-4 proteins, a symptom of bio-incompatibility.
  • silicones may be folded, when released they tend to snap back or regain their unfolded shape too rapidly, posing a threat to the integrity of the endothelial cell layer of the eye.
  • the long term stability of UV-absorbing silicone formulations is uncertain.
  • hydrogels it has been found that hydrogel materials when hydrated vary in composition including water content from lot to lot. Such variability induces a corresponding variability in the refractive power of IOL lens bodies formed of hydrogel material.
  • hydrogel IOLs need to be hydrated in order to determine their refractive power in implanted state.
  • hydrated lenses cannot be safely stored in the wet state without losing sterilization. If they are dehydrated subsequently, the process of hydrothermal cycling reduces the tensile strength of the IOL material and may cause cracks or crazes to develop in the lens body.
  • deformable IOLs have been described in U.S. Pat. Nos. 4,573,998 and 4,608,049. More specifically, the '998 patent is directed to methods for implantation of deformable IOLs.
  • the patent describes an IOL having an optical zone portion composed of materials such as polyurethane elastomers, silicone elastomers, hydrogel polymer collagen compounds, organic or synthetic gel compounds and combinations thereof. In practice, such materials possess the disadvantages previously attributed to silicone and hydrogen materials.
  • the '049 patent describes two basic types of deformable IOLs.
  • the firs type includes a lens body of one or more rigid portions hinged or otherwise connected to overlap each other when it is desired to reduce the profile of thelens body as during implantation of the lens. Such lens configurations are difficult to construct and to manipulate during implantation and further suffer from the limitations associated with rigid IOLs.
  • the second type of IOL described by the '049 patent includes a deformable lens body characterized as being capable of return to an undeformed configuration after insertion into the eye.
  • the lens body may be of silicone rubber or an acrylate polymer with ethylene glycol dimethacrylate as a crosslinking agent producing a material of a rubber consistency.
  • the deformable lens body is secured to an L-shaped fixation member around which it may be curled during insertion into the eye.
  • the silicone rubber IOL of the '049 patent suffers from the limitations previously attributed to silicone IOLs.
  • the acrylate polymer lens body described in the '049 patent is a hydrogel of a relatively hard consistency (subject to the foreign problems attributed to hydrogels) while other acrylate polymers known to be pliable are prone to mechanical failure upon compression or folding and are subject to degradation in the eye.
  • the present invention comprises an IOL having a deformable-elastic transparent lens body of crosslinked acrylic material having a tensile strength sufficient to resist deformation after implantation into the eye as by forces exerted by growing tissue around the IOL; a flexibility as measured by elongation at break sufficient to allow the lens body to be readily folded, rolled or otherwise deformed to a low profile condition for implantation through a small incision into the eye; an elastic memory which enables the folded lens body to naturally and at a controlled rate return to its original shape and optical resolution without damaging or otherwise traumatizing eye tissue; and a low-tack surface which will not stick to surgical instruments used to hold and guide the lens body during insertion and positioning within the eye.
  • the crosslinked acrylic material comprises copolymers of methacrylate and acrylate esters which are relatively hard and relatively soft at body temperature, crosslinked with a diacrylate ester to produce an acrylic material having a substantially tack-free surface, a crosslink density between . .0.5 ⁇ 10 -2 and 1.5 ⁇ 10 -2 .!. .Iadd.0.23 ⁇ 10 -1 and 1.66 ⁇ 10 -1 .Iaddend.moles per liter, a glass transition temperature in the range of -30° and 25° C., a tensile modulus in the range of 1000 to 3000 psi and an elongation at a break between 100 and 300%.
  • Such a lens body is easily folded, rolled or otherwise deformed into a low profile for insertion through a small incision and after insertion will naturally return to its original optical resolution at a slow controlled rate in between 20 and 180 seconds even if the lens body has been deformed to a low profile condition for an extended period of time.
  • the slow return allows the surgeon adequate time to locate the folded IOL in the eye before the lens body returns to its original shape and resolution and insures that the unfolding of the lens will not damage or otherwise traumatize ocular tissue.
  • a lens body of the foregoing material and composition possesses a desired tensile strength to resist deformation in response to forces exerted by tissue growing around the implanted lens body thereby maintaining the desired optical characteristics and resolution of the lens body.
  • the copolymers of methacrylate and acrylate esters are mixed at approximately a 45 to 55 weight percent ratio and the relatively hard methacrylate ester is a fluoroacrylate.
  • the fluoroacrylate functions as a surface energy lowering agent as well as a monomer providing long term stable inertness and tensile strength to the polymer without adversely effecting the pliancy of the resulting material.
  • the fluoroacrylate is present in a concentration range by weight of between 5 and 25% and preferably is trifluoro ethyl methacrylate.
  • the mixture of the copolymers is partially polymerized prior to chemical crosslinking with diacrylate ester in a concentration range of between 0.5 and 3.0 percent by weight.
  • the resulting crosslinked acrylic material may be molded and formed into lens bodies machined to have the desired optical characteristics and resolution with haptics extending therefrom either integral with or separately attached to the lens body.
  • the crosslinked acrylic material formed according to the present invention is machined and otherwise processed at low temperatures in the range of -80° to -10° C. and preferably at -60° C.
  • the lens body is maintained at a temperature below its Beta-relaxation temperature where the material is even harder than at its glass transition temperature.
  • FIG. 1 is a front elevation view of an exemplary IOL formed in accordance with the novel features of the invention
  • FIG. 2 is a side elevation view of the IOL depicted in FIG. 1;
  • FIG. 3 is a fragmented front elevation view depicting the IOL of FIG. 1 implanted into the posterior chamber of an eye;
  • FIG. 4 is an enlarged perspective view illustrating the lens of FIG. 1 rolled into a reduced size profile prior to implantation
  • FIG. 5 is a fragmented sectional view illustrating implantation of the lens into the posterior chamber of the eye
  • FIG. 6 is a graphic representation of the relative stiffness of the body of the IOL as a function of temperature
  • FIG. 7 is a flow diagram in block form illustrating a preferred form of a method for producing a deformable-elastic acrylic material comprising a lens body of an IOL in accordance with the present, invention
  • FIGS. 8A and 8B illustrate two molds useful in the method of the present invention for forming acrylic material into intraocular lens bodies
  • FIG. 9 is a plan view of a bottom part of a mold useful in forming a one piece IOL in accordance with the present invention.
  • FIG. 9 also illustrates a plan view of the part produced from such a mold.
  • an improved IOL is referred to generally by the reference numeral 10 in FIGS. 1-5.
  • the improved lens 10 is deformable (FIGS. 4 and 5) to a reduced profile size to permit implantation into an eye 12 through a relatively small incision 14.
  • the lens 10 is formed with a selected set of physical characteristics to expand within the eye slowly but substantially completely to its initial nondeformed state and optical resolution without trauma to delicate eye tissue.
  • the IOL 10 of the present invention comprises a traditional disk-shaped lens body 16 having an appropriate diametric typically on the order of about six millimeters and a combination of surface shapes on the anterior-posterior sides to provide selected dioptic characteristics, with a convexo-plano shape being shown by way of example in the illustrative drawings.
  • the IOL 10 is adapted for implantation into the eye 12 subsequent to surgical removal of the natural crystalline lens, typically due to a cataract conditions. Alternately, if desired, the IOL can be implanted to obtain refractive correction of the natural lens.
  • Support structures such as a pair of outwardly radiating and curved resilient loops or haptics 18 are secured to the lens body 16 and function to support the lens body within the eye 12, as will be described in more detail.
  • the haptics 18 may be anteriorly angulated as shown in FIG. 2, and/or provided into other configurations such as a trio of loops or alternate support structures formed integrally with the lens body, in accordance with the particular intraocular lens design.
  • the IOL 10 is adapted for implantation into the eye through an incision 14 formed in the ocular tissue at a position removed from a normal sight line passing through the transparent cornea 19, as viewed in FIG. 5, and further through the pupil 20 defined by the iris 22.
  • the IOL 10 can be designed as shown in FIG. 5 for implantation through the pupil 20 into to so-called posterior chamber 24 behind the iris 22, typically within a capsular bag 26 which has been anteriorly ruptured in the course of extracapsular extrusion of the natural crystalline lens.
  • the IOL 10 can be implemented into the anterior chamber 28 at the front side of the iris 22.
  • support structures such as the illustrative pair of outwardly curing support loops 18 seat against surrounding tissue at the chamber periphery of retain the lens body 16 generally centered on the normal line of sight.
  • Positioning holes 32 may also be provided near the periphery of the lens body 16 and are easily engaged by appropriate surgical instruments (not shown) to facilitate lens manipulation by the surgeon to the desired position within the eye.
  • the lens body 16 of the IOL is formed from a deformable-elastic transparent crosslinked acrylic material with a unique balance of flexibility, elasticity, tensile strength and softness properties yielding significant advantages during implantation and subsequent use. More specifically, because of its improved flexibility, the IOL is capable of being reduced in profile size to fit through the incision 14 of reduced size in comparison with conventional hard plastic lens of polymethylmethacrylate (PMMA) or the like. Because of its controlled elasticity, the lens body 16 anchors the haptics 18 with sufficient damping to prevent rapid or snap-action movement of the haptics 18 toward their normal unstressed configurations, thereby preventing the haptics from sharply striking and damaging eye tissue.
  • PMMA polymethylmethacrylate
  • the lens body possess a relatively slow speed of return or retraction of about twenty (20) to one-hundred eighty (180) seconds from a deformed state as shown in FIG. 4 to its initial undeformed state to avoid striking and damaging eye tissue. Further, the lens body has excellent elastic memory to insure substantially complete return to the undeformed state without plastic deformation.in the form of fold lines or creases or other distortions which would otherwise impair optical quality.
  • the preferred crosslinked acrylic material for the IOL 10 comprises copolymers of methacrylate and acrylate esters which are relatively hard and relatively soft at body temperature, partially polymerized, chemically crosslinked with a diacrylate ester and cured.
  • the resulting acrylic has a relatively leathery characteristics at temperature conditions corresponding with or approximating body temperature.
  • the crosslinked acrylic composition is selected to have a glass transition temperature (Tg) somewhat below body temperature so that the lens will exhibit a stiffness (Young's modulus) at a body temperature environment reflecting a relatively leathery characteristic.
  • Tg glass transition temperature
  • Youngng's modulus Youngng's modulus
  • the crosslinked acrylic composition is chosen to have highly elastic or viscoelastic properties with substantially no plastic deformation and a relatively slow speed of retraction.
  • the IOL 10 can be deformed as by rolling upon itself together with the haptic 18 as viewed in FIGS. 4 and 5 for facilitated implantation via a small insertion tube 36 passed through the small incision 14.
  • the hollow insertion tube 36 may be prefilled with Healon or the like for lubrication purposes.
  • the IOL 10, including the lens body 16 and haptics 18, may be temperature prepared in advance substantially at body temperature, at which time the IOL 10 and tube 36 are advanced through the incision 14 and into the eye, for example, within the posterior chamber 24, where the lens is expelled from the tube 36 within the eye. The thus-released lens is allowed to return to its initial nondeformed state.
  • this return movement takes place slowly with excellent elastic memory over a time of at least about twenty seconds.
  • the lens position within the eye can be manipulated with appropriate instruments engaging, for example, the positioning holes 32 after which the incision is closed to complete the procedure.
  • the preferred lens body composition is prepared by copolymerization of transparent acrylic and methacrylic monomers which otherwise exhibit relatively hard and relatively soft physical characteristics in a body temperature environment and a glass transition temperature (Tg) within the range of about -30° to about 25° C. and more preferably 0° C.
  • the monomers include a fluorometer for enhancing the tack-free inertness and tensile strength of characteristics of the lens body within the eye and the resulting acrylic is produced by chemical crosslinking with a diacrylate ester to form a stable interpenetrating polymer network having the desired elasticity and elastic memory characteristics.
  • FIG. 7 A preferred form of the method for forming the copolymer is depicted in FIG. 7.
  • ethyl methacrylate is mixed with n-butyl acrylate or ethyl acrylate preferably in a weight percent concentration of 34% to 52% respectively.
  • the mixture includes 10% by weight of a fluoroacrylate functioning as a surface energy lowering agent.
  • fluoroacrylates may be perfluoro octal methacrylate or more preferably trifluoroethyl methacrylate.
  • the n-butyl acrylate or ethyl acrylate provides flexibility in the presence of methacrylate esters principally because of the low glass transition temperature thereof.
  • the n-butyl acrylate or ethyl acrylate renders the mixture tacky or sticky. Such tackiness is minimized by the fluoracrylate particularly trifluoroethyl methacrylate.
  • the mixture includes a UV-absorber, UV-2098 and a free radical initiator, preferably USP 245, which is one in a class of aliphatic peroxides.
  • the UV-absorber and initiator are present at 1.5 and 0.05% by weight concentrations.
  • the combination is mixed, deaerated and placed in an oven at about 60° C. for two hours.
  • the mixture undergoes partial polymerization to form a viscous syrupy liquid when cooled to about 25° C.
  • the viscous syrupy liquid may be stored for several days at -15° C. for subsequent mixing with a crosslinking agent and free radical initiator.
  • An alternate method of preparing the syrup is to dissolve low molecular weight (number average molecular weight between 30,000-50,000) polymers such as poly(ethyl methacrylate) and poly(n-butyl acrylate) in the same relative concentrations at a polymer - monomer ratio ranging from 1:5 to 1:3.
  • the syrup may be filtered through a 0.2 micron filter immediately prior to use.
  • the crosslinking agent may consist of ethylene glycol dimethacrylate.
  • the crosslinking agent may be propylene glycol dimethacrylate or ethylene glycol diacrylate.
  • the crosslinking agent is mixed in a weight percent concentration of about 2.5 to produce a crosslinked density for the resulting copolymer in a range of . .0.5 ⁇ 10 -2 to 1.5 ⁇ 10 -2 .!. .Iadd.0.23 ⁇ 10 -1 and 1.66 ⁇ 10 -1 .Iaddend.moles per liter.
  • Such a crosslinking density provides the resulting polymer with the desired elastic memory and elasticity.
  • the resulting lens bodies 16 upon being folded, the resulting lens bodies 16 will return to its initial state naturally in about 20 to 180 seconds and preferably about 30 seconds.
  • the syrup, crosslinking agent and initiator (in the indicated percent by weight concentrations) are mixed, deareated and the resulting mixture poured into a mold such as mold number 1 or 2 illustrated in FIG. 8A and B or the mold illustrated in FIG. 9.
  • a mold such as mold number 1 or 2 illustrated in FIG. 8A and B or the mold illustrated in FIG. 9.
  • the resulting mixture is poured onto an aluminum plate 1 bounded by rubber gaskets 2.
  • a glass plate 3 is placed on top of the rubber gaskets and the combination clamped together by clamps 4.
  • the mold is placed in an oven, heated to about 60° C. and cured for about 16 hours.
  • the mold is then post cured at about 90° C. for 24 hours.
  • the mold After curing, the mold is disassembled and the sheets formed therein made ready for cutting into cylindrical lens blanks in the case of mold number 1 for deflashing into lens bodies in the case of mold number 2.
  • the mold bottom shown in FIG. 9 may be used. As illustrated, the mold has slots machined into its aluminum base to accommodate the haptics at an appropriate angle.
  • the molded part from the mold of FIG. 9 comprises the optic and the haptic elements encased in a thin sheet of flash which may be machined off to produce the finished IOL.
  • Such cutting and machining to produce the desired IOL may involve conventional milling and lathe techniques with the exception that the part is held at a temperature well below room temperature and preferably between -80° and -10° C. Specifically, it is desired that the material be held below its Beta-relaxation temperature during cutting.
  • the low temperature environment is formed by exposing the part to a liquid nitrogen spray which maintains the part within the desired temperature range and provides the desired moisture for the cutting operation.
  • the copolymer material possesses a particularly hard characteristic suitable for high speed and efficient cutting.
  • An example of a procedure used to fabricate a multi-piece IOL as shown in FIG. 1 including separate haptics is as follows. First, flat sheets of the crosslinked acrylic are molded at a thickness of between 2 mm and 8 mm as described above and mounted on holders. The material is then cut into disks which are lathe cut at the low temperatures previously described to form the curved planar surfaces and edge cut. The resulting lens bodies are soaked in Freon and chlorofluoro hydrocarbon solvents for 20 minutes and then dried for 30 minutes in a vacuum oven at 60° C. The curved surfaces of the lens bodies are then polished at a low temperature. Next, the lens bodies are mounted for drilling of the positioning holes 32 as well as the edge holes for receiving the haptics 18.
  • the positioning holes are typically 0.3 mm while the edge holes for receiving the haptics are typically 0.1 mm in diameter.
  • the haptics are located in a stainless steel needle and one end of the haptic melted to form a thickened blunt tip. The needle is then inserted into the edge hole to force the blunt end of the haptic into the hole at room temperature. The needle is carefully withdrawn allowing the walls of the edge hole to collapse back to their normal position clamping the haptic in place. This operation is then repeated for the other haptic.
  • the sheet is cored in the area of the lens bodies to cut the lens bodies from the sheet.
  • the resulting lens bodies are then mounted in suitable holders and the foregoing procedure repeated.
  • the flash may be removed on a mill to form the desired one piece IOL.
  • the IOLs of the present invention may be provided in various geometries adapted for folding or rolling, etc. to a reduced profile configuration thereby permitting implantation into the eye through an incision of reduced size.
  • the deformed lens returns to its original nondeformed state.
  • the lens is formed from a material having a combination of excellent elastic memory and slow speed of retraction characteristics. The lens thus returns slowly to the nondeformed state without injuring eye tissue while achieving the final nondeformed state without creases, wrinkles, or other structural deviations which would otherwise result in optical distortions.

Abstract

A deformable-elastic intraocular lens comprising a deformable-elastic lens body of crosslinked acrylic material formed of copolymers of methacrylate and acrylate esters which are relatively hard and relatively soft at body temperature, crosslinked with a diacrylate ester to produce an acrylic copolymer having a substantially tack-free surface, a crosslink density of between . .0.5×10-2 and 1.5×10-2 .!. .Iadd.0.23×10-1 and 1.66×10-1 .Iaddend.moles per liter, and glass transition temperature in the range of -30° C. to 25° C., a tensile modulus between 1000 and 3000 psi and a elongation a break of 100% or greater.

Description

BACKGROUND OF THE INVENTION
The present invention relates generally to improvements in intraocular lenses (IOLs) designed for surgical implantation into the eye, for example, as a replacement for a cataractous or injured natural lens. More specifically, the invention relates to improvements in deformable IOLs which can be folded or rolled to a relatively low profile size to fit into the eye through a relatively small incision, and then within the eye naturally return to an internal nondeformed shape with predetermined optical properties.
IOLs are well known in the art for implantation into the eye as a replacement for a natural crystalline lens which has been surgically removed typically due to opacification, commonly referred to as a cataract condition. Such IOLs have been formed from a small disk of transparent glass or plastic material having appropriately shaped lens surfaces to achieve a desired set of optical properties. The IOL is implanted directly into the eye, typically after removal of the natural crystalline lens, via an incision formed in ocular tissue such as the scalera outside the normal line of sight. Many IOLs are designed for implantation into the so-called posterior chamber of the eye behind the iris and pupil, whereas other IOLs are adapted for placement into the anterior chamber in front of the iris and pupil. In most IOL designs, support structures are attached to or formed integrally with a central lens body or optic and project outwardly therefrom to contact eye tissue at the periphery of the posterior or anterior chamber, thereby retaining the lens body or optic in generally centered relation with the line of sight passing through the pupil.
In the past, most IOLs have been formed from polymethylmethacrylate (PMMA) which is relatively light in weight, possesses excellent optical properties, and is generally considered to be relatively inert when implanted into the eye, thereby avoiding adverse tissue reactions. However, PMMA comprises a plastic matrix which, when formed into the shape of a lens, possesses high rigidity and cannot be deformed by folding, rolling, compression, etc. Accordingly, the use of PMMA lenses requires a relatively large incision in the ocular tissue sufficient to accommodate the entire diametric size of the lens body; which is typically six millimeters or larger, together with the accompanying lens supports structures. Although the resilient lens support structures such a polypropylene loops or haptics are commonly used and advantageously may be folded over the lens body during insertion, such resilient haptics are anchored into the periphery of the hard plastic lens body and thus tend to spring back to their initial unfolded shape with a rapid snap like action during IOL implantation, resulting in undesired trauma to sensitive eye tissues.
While IOLs with rigid PMMA lens bodies have gained widespread acceptance and use, it has been recognized that deformable IOLs have the potential of providing medical benefits well beyond those associated with current IOLs including rigid lens bodies. More particularly, an IOL including a deformable transparent lens body which may be folded or rolled into a reduced profile size may fit through a relatively small incision in ocular tissue and after insertion and release within the eye return to its original size and shape by virtue of its natural resilience. The use of a smaller incision would beneficially result in a safer overall surgical procedure requiring fewer stitches and reduced likelihood of postoperative complications such as infections. In addition, a smaller incision would reduce the incidence of postoperative astigmatism and substantially reduce rehabilitation time. Second, it is anticipated that IOLs with deformable lens bodies may reduce the potential for complications secondary to contact or rubbing against delicate uveal tissues. Also, deformable IOLs may decrease the potential for pigmentary dispersion or pigmentary glaucoma. Finally, it is anticipated that the formable IOLs will provide an added margin of safety for patients with blood dyscarsias, coagulopalthies and hematologic matogrant disease as well as those patients being given anti-coagulant therapy.
Accordingly, deformable IOLs formed of silicones and hydrogels have been proposed for implantation. For example, in 1983, Fyodorov reported on chemical testing of a silicone IOL (Fyodorov, S. W. et al "Initial Clinical Testing of a Silicone Intraocular Lens" Interzonal Scientific/Practical Conference of Ophthalmologists of Western and Eastern Siberia and the Far East, Conference Proceedings 4: 22-24, 1983, Vladivostock). Also in 1983, Mazzacco and Davidson presented initial data on the implantation of silicone IOLs with 6 mm optical zones through 3 mm incisions (Mazzacco, T. R. and Davidson, V. A. "6 mm Optic for a 3 mm Wound" presented at the A.I.O.I.S. United States Intraocular Lens Symposium, New Orleans, La., March 1983). Wichterle and his associates developed a hydrogel of hydrophilic polyacrylates for orbital and intracameral implants in 1960 while Epstein implanted flexible IOLs comprised of poly(hydro hydroxyethyl methacrylate) in 1976 and 1977. The condition of some patients implanted with such lens was followed until 1984 ("Insertion Techniques and Clinical Experience with HEMA Lenses" Soft Implant Lenses in Cataract Surgery T. R. Mazzacco, G. M. Rajacich, E. Epstein, published by Slack Inc., 1986, pp. 11).
Unfortunately, silicones and hydrogels have several well documented deficiencies which hinder their use as IOL materials. In particular, silicones cause complement activation leading to the production of C-4 proteins, a symptom of bio-incompatibility. Also, while silicones may be folded, when released they tend to snap back or regain their unfolded shape too rapidly, posing a threat to the integrity of the endothelial cell layer of the eye. In addition, the long term stability of UV-absorbing silicone formulations is uncertain. As for hydrogels, it has been found that hydrogel materials when hydrated vary in composition including water content from lot to lot. Such variability induces a corresponding variability in the refractive power of IOL lens bodies formed of hydrogel material. Therefore, hydrogel IOLs need to be hydrated in order to determine their refractive power in implanted state. Unfortunately, hydrated lenses cannot be safely stored in the wet state without losing sterilization. If they are dehydrated subsequently, the process of hydrothermal cycling reduces the tensile strength of the IOL material and may cause cracks or crazes to develop in the lens body.
Other deformable IOLs have been described in U.S. Pat. Nos. 4,573,998 and 4,608,049. More specifically, the '998 patent is directed to methods for implantation of deformable IOLs. The patent describes an IOL having an optical zone portion composed of materials such as polyurethane elastomers, silicone elastomers, hydrogel polymer collagen compounds, organic or synthetic gel compounds and combinations thereof. In practice, such materials possess the disadvantages previously attributed to silicone and hydrogen materials.
The '049 patent describes two basic types of deformable IOLs. The firs type includes a lens body of one or more rigid portions hinged or otherwise connected to overlap each other when it is desired to reduce the profile of thelens body as during implantation of the lens. Such lens configurations are difficult to construct and to manipulate during implantation and further suffer from the limitations associated with rigid IOLs. The second type of IOL described by the '049 patent includes a deformable lens body characterized as being capable of return to an undeformed configuration after insertion into the eye. The lens body may be of silicone rubber or an acrylate polymer with ethylene glycol dimethacrylate as a crosslinking agent producing a material of a rubber consistency. The deformable lens body is secured to an L-shaped fixation member around which it may be curled during insertion into the eye. The silicone rubber IOL of the '049 patent suffers from the limitations previously attributed to silicone IOLs. The acrylate polymer lens body described in the '049 patent is a hydrogel of a relatively hard consistency (subject to the foreign problems attributed to hydrogels) while other acrylate polymers known to be pliable are prone to mechanical failure upon compression or folding and are subject to degradation in the eye.
In viewing of the foregoing, it is apparent that there is a need for an intraocular lens and lens material having an improved balance of superior optical characteristics, flexibility, elasticity, elastic memory, and tensile strength. The present invention satisfies such needs.
SUMMARY OF THE INVENTION
Generally speaking, the present invention comprises an IOL having a deformable-elastic transparent lens body of crosslinked acrylic material having a tensile strength sufficient to resist deformation after implantation into the eye as by forces exerted by growing tissue around the IOL; a flexibility as measured by elongation at break sufficient to allow the lens body to be readily folded, rolled or otherwise deformed to a low profile condition for implantation through a small incision into the eye; an elastic memory which enables the folded lens body to naturally and at a controlled rate return to its original shape and optical resolution without damaging or otherwise traumatizing eye tissue; and a low-tack surface which will not stick to surgical instruments used to hold and guide the lens body during insertion and positioning within the eye. In particular, the crosslinked acrylic material comprises copolymers of methacrylate and acrylate esters which are relatively hard and relatively soft at body temperature, crosslinked with a diacrylate ester to produce an acrylic material having a substantially tack-free surface, a crosslink density between . .0.5×10-2 and 1.5×10-2 .!. .Iadd.0.23×10-1 and 1.66×10-1 .Iaddend.moles per liter, a glass transition temperature in the range of -30° and 25° C., a tensile modulus in the range of 1000 to 3000 psi and an elongation at a break between 100 and 300%. Such a lens body is easily folded, rolled or otherwise deformed into a low profile for insertion through a small incision and after insertion will naturally return to its original optical resolution at a slow controlled rate in between 20 and 180 seconds even if the lens body has been deformed to a low profile condition for an extended period of time. The slow return allows the surgeon adequate time to locate the folded IOL in the eye before the lens body returns to its original shape and resolution and insures that the unfolding of the lens will not damage or otherwise traumatize ocular tissue. Furthermore, a lens body of the foregoing material and composition possesses a desired tensile strength to resist deformation in response to forces exerted by tissue growing around the implanted lens body thereby maintaining the desired optical characteristics and resolution of the lens body.
Preferably, in the formation of the deformable-elastic acrylic material, the copolymers of methacrylate and acrylate esters are mixed at approximately a 45 to 55 weight percent ratio and the relatively hard methacrylate ester is a fluoroacrylate. The fluoroacrylate functions as a surface energy lowering agent as well as a monomer providing long term stable inertness and tensile strength to the polymer without adversely effecting the pliancy of the resulting material. In this regard, the fluoroacrylate is present in a concentration range by weight of between 5 and 25% and preferably is trifluoro ethyl methacrylate. Also in the preferred formulation of the crosslinked acrylic, the mixture of the copolymers is partially polymerized prior to chemical crosslinking with diacrylate ester in a concentration range of between 0.5 and 3.0 percent by weight.
The resulting crosslinked acrylic material may be molded and formed into lens bodies machined to have the desired optical characteristics and resolution with haptics extending therefrom either integral with or separately attached to the lens body. Preferably, the crosslinked acrylic material formed according to the present invention is machined and otherwise processed at low temperatures in the range of -80° to -10° C. and preferably at -60° C. In particular, during cutting the lens body is maintained at a temperature below its Beta-relaxation temperature where the material is even harder than at its glass transition temperature.
BRIEF DESCRIPTION OF THE DRAWINGS
The accompanying drawings illustrate the invention. In such drawings:
FIG. 1 is a front elevation view of an exemplary IOL formed in accordance with the novel features of the invention;
FIG. 2 is a side elevation view of the IOL depicted in FIG. 1;
FIG. 3 is a fragmented front elevation view depicting the IOL of FIG. 1 implanted into the posterior chamber of an eye;
FIG. 4 is an enlarged perspective view illustrating the lens of FIG. 1 rolled into a reduced size profile prior to implantation;
FIG. 5 is a fragmented sectional view illustrating implantation of the lens into the posterior chamber of the eye;
FIG. 6 is a graphic representation of the relative stiffness of the body of the IOL as a function of temperature;
FIG. 7 is a flow diagram in block form illustrating a preferred form of a method for producing a deformable-elastic acrylic material comprising a lens body of an IOL in accordance with the present, invention;
FIGS. 8A and 8B illustrate two molds useful in the method of the present invention for forming acrylic material into intraocular lens bodies; and
FIG. 9 is a plan view of a bottom part of a mold useful in forming a one piece IOL in accordance with the present invention. FIG. 9 also illustrates a plan view of the part produced from such a mold.
DETAILED DESCRIPTION
As shown in the exemplary drawings, one preferred form of an improved IOL is referred to generally by the reference numeral 10 in FIGS. 1-5. The improved lens 10 is deformable (FIGS. 4 and 5) to a reduced profile size to permit implantation into an eye 12 through a relatively small incision 14. The lens 10 is formed with a selected set of physical characteristics to expand within the eye slowly but substantially completely to its initial nondeformed state and optical resolution without trauma to delicate eye tissue.
As shown in FIGS. 1, 2 and 3, the IOL 10 of the present invention comprises a traditional disk-shaped lens body 16 having an appropriate diametric typically on the order of about six millimeters and a combination of surface shapes on the anterior-posterior sides to provide selected dioptic characteristics, with a convexo-plano shape being shown by way of example in the illustrative drawings. The IOL 10 is adapted for implantation into the eye 12 subsequent to surgical removal of the natural crystalline lens, typically due to a cataract conditions. Alternately, if desired, the IOL can be implanted to obtain refractive correction of the natural lens. Support structures such as a pair of outwardly radiating and curved resilient loops or haptics 18 are secured to the lens body 16 and function to support the lens body within the eye 12, as will be described in more detail. The haptics 18 may be anteriorly angulated as shown in FIG. 2, and/or provided into other configurations such as a trio of loops or alternate support structures formed integrally with the lens body, in accordance with the particular intraocular lens design.
In accordance with known intraocular lens implantation techniques, the IOL 10 is adapted for implantation into the eye through an incision 14 formed in the ocular tissue at a position removed from a normal sight line passing through the transparent cornea 19, as viewed in FIG. 5, and further through the pupil 20 defined by the iris 22. The IOL 10 can be designed as shown in FIG. 5 for implantation through the pupil 20 into to so-called posterior chamber 24 behind the iris 22, typically within a capsular bag 26 which has been anteriorly ruptured in the course of extracapsular extrusion of the natural crystalline lens. Alternately, if desired, the IOL 10 can be implemented into the anterior chamber 28 at the front side of the iris 22. In either case, support structures such as the illustrative pair of outwardly curing support loops 18 seat against surrounding tissue at the chamber periphery of retain the lens body 16 generally centered on the normal line of sight. Positioning holes 32 may also be provided near the periphery of the lens body 16 and are easily engaged by appropriate surgical instruments (not shown) to facilitate lens manipulation by the surgeon to the desired position within the eye.
In accordance with primary aspects of the invention, the lens body 16 of the IOL is formed from a deformable-elastic transparent crosslinked acrylic material with a unique balance of flexibility, elasticity, tensile strength and softness properties yielding significant advantages during implantation and subsequent use. More specifically, because of its improved flexibility, the IOL is capable of being reduced in profile size to fit through the incision 14 of reduced size in comparison with conventional hard plastic lens of polymethylmethacrylate (PMMA) or the like. Because of its controlled elasticity, the lens body 16 anchors the haptics 18 with sufficient damping to prevent rapid or snap-action movement of the haptics 18 toward their normal unstressed configurations, thereby preventing the haptics from sharply striking and damaging eye tissue. Moreover, the lens body possess a relatively slow speed of return or retraction of about twenty (20) to one-hundred eighty (180) seconds from a deformed state as shown in FIG. 4 to its initial undeformed state to avoid striking and damaging eye tissue. Further, the lens body has excellent elastic memory to insure substantially complete return to the undeformed state without plastic deformation.in the form of fold lines or creases or other distortions which would otherwise impair optical quality.
The preferred crosslinked acrylic material for the IOL 10 comprises copolymers of methacrylate and acrylate esters which are relatively hard and relatively soft at body temperature, partially polymerized, chemically crosslinked with a diacrylate ester and cured. The resulting acrylic has a relatively leathery characteristics at temperature conditions corresponding with or approximating body temperature. More specifically, with reference to FIG. 6, the crosslinked acrylic composition is selected to have a glass transition temperature (Tg) somewhat below body temperature so that the lens will exhibit a stiffness (Young's modulus) at a body temperature environment reflecting a relatively leathery characteristic. In addition, the crosslinked acrylic composition is chosen to have highly elastic or viscoelastic properties with substantially no plastic deformation and a relatively slow speed of retraction. With such a combination of characteristics, the IOL 10 can be deformed as by rolling upon itself together with the haptic 18 as viewed in FIGS. 4 and 5 for facilitated implantation via a small insertion tube 36 passed through the small incision 14. In particular, the hollow insertion tube 36 may be prefilled with Healon or the like for lubrication purposes. The IOL 10, including the lens body 16 and haptics 18, may be temperature prepared in advance substantially at body temperature, at which time the IOL 10 and tube 36 are advanced through the incision 14 and into the eye, for example, within the posterior chamber 24, where the lens is expelled from the tube 36 within the eye. The thus-released lens is allowed to return to its initial nondeformed state. Importantly, this return movement takes place slowly with excellent elastic memory over a time of at least about twenty seconds. When the lens is substantially completely expanded, the lens position within the eye can be manipulated with appropriate instruments engaging, for example, the positioning holes 32 after which the incision is closed to complete the procedure.
The preferred lens body composition is prepared by copolymerization of transparent acrylic and methacrylic monomers which otherwise exhibit relatively hard and relatively soft physical characteristics in a body temperature environment and a glass transition temperature (Tg) within the range of about -30° to about 25° C. and more preferably 0° C. Preferably, the monomers include a fluorometer for enhancing the tack-free inertness and tensile strength of characteristics of the lens body within the eye and the resulting acrylic is produced by chemical crosslinking with a diacrylate ester to form a stable interpenetrating polymer network having the desired elasticity and elastic memory characteristics.
The following chart lists various monomers which after purification, as by vacuum distillation, may be used in preparing the desired copolymer of crosslinked acrylic material as well as the concentration ranges for such monomers in percent by weight and preferred compositions I and II in percent by weight composition.
______________________________________
                     Preferred
               Concentration
                           Compositions %
Monomer        Range %     I        II
______________________________________
Ethyl Methacrylate
               25-15       34       34
Trifluoro Ethyl
                5-25       10       10
Methacrylate
n-Butyl Acrylate
               30-60       52       0
Ethyl Acrylate 30-60       0        52
2-Ethyl Hexyl Acrylate
               30-60       0        0
2-Hydroxy 4-Ethyloxy-
                0-10       1.5      1.5
Acryloxy Benzophenone
(UV-2098)
2,5 Dimethyl-2,5
               0.05-0.2    0.15     0.15
Bio (2-Ethyl Hydroxyl
Droxyl) Hexane (USP 245)
Ethylene Glycol
               0.5-3.0     2.5      2.5
Dimethyacrylate
______________________________________
A preferred form of the method for forming the copolymer is depicted in FIG. 7. As there represented, ethyl methacrylate is mixed with n-butyl acrylate or ethyl acrylate preferably in a weight percent concentration of 34% to 52% respectively. In addition to the methacrylate and acrylate esters of ethyl methacrylate and n-butyl acrylate or ethyl acrylate, the mixture includes 10% by weight of a fluoroacrylate functioning as a surface energy lowering agent. Such fluoroacrylates may be perfluoro octal methacrylate or more preferably trifluoroethyl methacrylate. In the mixture, the n-butyl acrylate or ethyl acrylate provides flexibility in the presence of methacrylate esters principally because of the low glass transition temperature thereof. However, the n-butyl acrylate or ethyl acrylate renders the mixture tacky or sticky. Such tackiness is minimized by the fluoracrylate particularly trifluoroethyl methacrylate. In addition to the foregoing, and as represented in FIG. 7, the mixture includes a UV-absorber, UV-2098 and a free radical initiator, preferably USP 245, which is one in a class of aliphatic peroxides. The UV-absorber and initiator are present at 1.5 and 0.05% by weight concentrations. The combination is mixed, deaerated and placed in an oven at about 60° C. for two hours. The mixture undergoes partial polymerization to form a viscous syrupy liquid when cooled to about 25° C. The viscous syrupy liquid may be stored for several days at -15° C. for subsequent mixing with a crosslinking agent and free radical initiator.
An alternate method of preparing the syrup is to dissolve low molecular weight (number average molecular weight between 30,000-50,000) polymers such as poly(ethyl methacrylate) and poly(n-butyl acrylate) in the same relative concentrations at a polymer - monomer ratio ranging from 1:5 to 1:3. The syrup may be filtered through a 0.2 micron filter immediately prior to use.
Again, as represented in FIG. 7, the crosslinking agent may consist of ethylene glycol dimethacrylate. Alternatively, the crosslinking agent may be propylene glycol dimethacrylate or ethylene glycol diacrylate. In each case, the crosslinking agent is mixed in a weight percent concentration of about 2.5 to produce a crosslinked density for the resulting copolymer in a range of . .0.5×10-2 to 1.5×10-2 .!. .Iadd.0.23×10-1 and 1.66×10-1 .Iaddend.moles per liter. Such a crosslinking density provides the resulting polymer with the desired elastic memory and elasticity. In particular, upon being folded, the resulting lens bodies 16 will return to its initial state naturally in about 20 to 180 seconds and preferably about 30 seconds.
To produce an IOL 10 with the lens body 16 having the foregoing characteristics, and as further depicted in FIGS. 7, 8A and B and 9, the syrup, crosslinking agent and initiator (in the indicated percent by weight concentrations) are mixed, deareated and the resulting mixture poured into a mold such as mold number 1 or 2 illustrated in FIG. 8A and B or the mold illustrated in FIG. 9. With respect to molds of FIG. 8, the resulting mixture is poured onto an aluminum plate 1 bounded by rubber gaskets 2. A glass plate 3 is placed on top of the rubber gaskets and the combination clamped together by clamps 4. The mold is placed in an oven, heated to about 60° C. and cured for about 16 hours. The mold is then post cured at about 90° C. for 24 hours.
After curing, the mold is disassembled and the sheets formed therein made ready for cutting into cylindrical lens blanks in the case of mold number 1 for deflashing into lens bodies in the case of mold number 2. Alternatively, the mold bottom shown in FIG. 9 may be used. As illustrated, the mold has slots machined into its aluminum base to accommodate the haptics at an appropriate angle. The molded part from the mold of FIG. 9 comprises the optic and the haptic elements encased in a thin sheet of flash which may be machined off to produce the finished IOL.
Such cutting and machining to produce the desired IOL may involve conventional milling and lathe techniques with the exception that the part is held at a temperature well below room temperature and preferably between -80° and -10° C. Specifically, it is desired that the material be held below its Beta-relaxation temperature during cutting. Preferably, during cutting, the low temperature environment is formed by exposing the part to a liquid nitrogen spray which maintains the part within the desired temperature range and provides the desired moisture for the cutting operation. As previously noted, at or below its Beta-relaxation temperature, the copolymer material possesses a particularly hard characteristic suitable for high speed and efficient cutting.
An example of a procedure used to fabricate a multi-piece IOL as shown in FIG. 1 including separate haptics is as follows. First, flat sheets of the crosslinked acrylic are molded at a thickness of between 2 mm and 8 mm as described above and mounted on holders. The material is then cut into disks which are lathe cut at the low temperatures previously described to form the curved planar surfaces and edge cut. The resulting lens bodies are soaked in Freon and chlorofluoro hydrocarbon solvents for 20 minutes and then dried for 30 minutes in a vacuum oven at 60° C. The curved surfaces of the lens bodies are then polished at a low temperature. Next, the lens bodies are mounted for drilling of the positioning holes 32 as well as the edge holes for receiving the haptics 18. The positioning holes are typically 0.3 mm while the edge holes for receiving the haptics are typically 0.1 mm in diameter. To mount the haptics into the edge holes, the haptics are located in a stainless steel needle and one end of the haptic melted to form a thickened blunt tip. The needle is then inserted into the edge hole to force the blunt end of the haptic into the hole at room temperature. The needle is carefully withdrawn allowing the walls of the edge hole to collapse back to their normal position clamping the haptic in place. This operation is then repeated for the other haptic.
Alternatively, for lens bodies molding using mold number 2 illustrated in FIG. 8B, the sheet is cored in the area of the lens bodies to cut the lens bodies from the sheet. The resulting lens bodies are then mounted in suitable holders and the foregoing procedure repeated.
Finally, for parts molded from the mold illustrated in FIG. 9, the flash may be removed on a mill to form the desired one piece IOL.
From the foregoing, it should be appreciated that the IOLs of the present invention may be provided in various geometries adapted for folding or rolling, etc. to a reduced profile configuration thereby permitting implantation into the eye through an incision of reduced size. Within the eye, the deformed lens returns to its original nondeformed state. However, according to the invention, the lens is formed from a material having a combination of excellent elastic memory and slow speed of retraction characteristics. The lens thus returns slowly to the nondeformed state without injuring eye tissue while achieving the final nondeformed state without creases, wrinkles, or other structural deviations which would otherwise result in optical distortions.
A variety of further modifications and improvements to the invention describe herein are believed to be apparent to those skilled in the art. Accordingly, no limitation is intended by way of the description herein, except as set forth in the appended claims.

Claims (21)

I claim:
1. A deformable-elastic intraocular lens (IOL), comprising:
a deformable-elastic lens body of crosslinked acrylic material comprising copolymers of methacrylate and a acrylate esters which are relatively hard and . .relative.!. .Iadd.relatively .Iaddend.soft at body temperature, crosslinked with a diacrylate ester wherein the crosslinked acrylic material has a substantially tack-free surface, a crosslink density of between . .0.5×10-2 and 1.5×10-2 .!. .Iadd.0.23×10-1 and 1.66×10-1 .Iaddend.moles per liter, a glass transition temperature between -30° and 25° C., a tensile modulus between 1000 and 3000 psi and an elongation at break of at least 100%; and
flexible haptics attached to the lens body to position the lens body in the eye.
2. The IOL of claim 1 wherein the lens body is formed by chemically crosslinking the diacrylate ester with a partially polymerized mixture of the copolymers, curing the crosslinked acrylic and holding the cured crosslinked acrylic at a temperature below its Beta-relaxation temperature while machining the lens body.
3. The IOL of claim 2 wherein each haptic is attached by forcing an enlarged end thereof into a smaller hole in an edge of the lens body.
4. A deformable-elastic intraocular lens (IOL), comprising:
a deformable-elastic lens body of crosslinked acrylic material formed by mixing copolymers of methacrylate and acrylate esters which are relatively hard and relatively soft at body temperature, with a diacrylate ester to produce an acrylic material having crosslinked density of between . .0.5×10-2 and 1.5×10-2 .!. .Iadd.0.23×10-1 and 1.66×10-1 .Iaddend.moles per liter and a glass transition temperature of between -30° and 25` C.; and
flexible haptics attached to the lens body to position the lens body in the eye.
5. The IOL of claim 4 wherein the copolymers are mixed and partially polymerized before mixing with the diacrylate ester.
6. A deformable-elastic intraocular lens body of a crosslinked acrylic material comprising copolymers of methacrylate and acrylate esters which are relatively hard and relatively soft at body temperature, crosslinked with a diacrylate ester wherein the acrylic material has a substantially tack-free surface, a crosslink density of between . .0.5×10-2 and 1.5×10-2 .!. .Iadd.0.23×10-1 and 1.66×10-1 .Iaddend.moles per liter, a glass transition temperature between -30° and 25° C., a tensile modulus between 1000 and 3000 psi and an elongation at break of at least 100%.
7. A deformable-elastic intraocular lens body of a crosslinked acrylic material formed by reacting copolymers of methacrylate and acrylate esters which are relatively hard and relatively soft at body temperature to produce a reaction product having a glass transition temperature between -30° and 25° C., partially polymerizing the reaction product and mixing it with a diacrylate ester to produce a crosslinked acrylic having a crosslink density of between . .0.5×10-2 and 1.5×10-2 .!. .Iadd.0.23×10-1 and 1.66×10-1 .Iaddend.moles per liter, curing the acrylic and machining the lens body therefrom.
8. The lens body of claim 7 wherein the relatively hard methacrylate ester is a fluoroacrylate.
9. The lens body of claim 7 wherein reaction product comprises ethyl methacrylate, trifluoro ethyl methacrylate and an acrylate ester present in percent by weight concentrations of 25 to 45, 5 to 25 and 30 to 60%, respectively.
10. The lens body of claim 9 wherein the acrylate ester is selected from n-butyl acrylate, ethyl acrylate and 2-ethyl hexyl acrylate.
11. The lens body of claim 10 wherein the diacrylate ester is present in a percent by weight concentration of 0.5 to 3.0%.
12. The lens of body of claim 11 wherein the diacrylate ester is selected from ethylene glycol dimethacrylate, propylene glycol dimethacrylate, and ethylene glycol diacrylate.
13. A method of forming a deformable-elastic intraocular lens body comprising the steps of:
(a) mixing copolymers of methacrylate and acrylate ester which are relatively hard and relatively soft at body temperature;
(b) partially polymerizing the product of Step (a);
(c) chemically crosslinking the product of Step (b) with a diacrylate ester;
(d) curing the product to Step (c); and
(e) forming a lens body having a predetermined optical characteristic from the product of Step (d).
14. The method of claim 13 wherein Step (e) comprises holding the product of Step (d) at a temperature below its Beta-relaxation temperature while machining the lens body.
15. The method of claim 13 wherein the methacrylate and acrylate esters are mixed together in approximately a 45 to 55% by weight ratio.
16. The method of claim 15 wherein the diacrylate ester of Step (C) is present in a percent composition by weight of 0.5 to 3.0%.
17. The method of claim 16 further including the mixing of a UV-absorber and a free radical initiator in Step (a).
18. The method of claim 13 wherein the relatively hard methacrylate ester is a fluoroacrylate.
19. The method of claim 18 wherein Step (a) further including mixing the fluoroacrylate in a concentration range by weight of between 5 and 25% with ethyl methacrylate in a concentration range by weight of between 25 and 45% and an acrylate ester selected from n-butyl acrylate, ethylacrylate or 2-ethyl hexyl acrylate in a concentration range by weight of between 30 and 60%.
20. The method of claim 19 wherein the fluoroacrylate is trifluoro ethyl methacrylate.
21. The method of claim 20 wherein Step (a) further includes the mixing of a UV-absorber in a concentration range by weight of between 0 and 10% and a free radical initiator in a concentration range by weight of 0.05 and 0.2%.
US08/538,757 1987-09-17 1995-10-03 Deformable-elastic intraocular lens Expired - Lifetime USRE36150E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/538,757 USRE36150E (en) 1987-09-17 1995-10-03 Deformable-elastic intraocular lens

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/099,293 US4834750A (en) 1987-09-17 1987-09-17 Deformable-elastic intraocular lens
US08/538,757 USRE36150E (en) 1987-09-17 1995-10-03 Deformable-elastic intraocular lens

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US07/099,293 Reissue US4834750A (en) 1987-09-17 1987-09-17 Deformable-elastic intraocular lens

Publications (1)

Publication Number Publication Date
USRE36150E true USRE36150E (en) 1999-03-16

Family

ID=22274275

Family Applications (2)

Application Number Title Priority Date Filing Date
US07/099,293 Ceased US4834750A (en) 1987-09-17 1987-09-17 Deformable-elastic intraocular lens
US08/538,757 Expired - Lifetime USRE36150E (en) 1987-09-17 1995-10-03 Deformable-elastic intraocular lens

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US07/099,293 Ceased US4834750A (en) 1987-09-17 1987-09-17 Deformable-elastic intraocular lens

Country Status (5)

Country Link
US (2) US4834750A (en)
EP (1) EP0308130B1 (en)
JP (1) JP2930306B2 (en)
CA (2) CA1330474C (en)
DE (1) DE3870779D1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245106B1 (en) 1998-10-29 2001-06-12 Allergan Sales, Inc. Intraocular lenses made from polymeric compositions and monomers useful in said compositions
US6283975B1 (en) * 1996-07-10 2001-09-04 Allergan Sales, Inc. IOL insertion apparatus and method for making and using same
US6398788B1 (en) * 1996-07-10 2002-06-04 Allergan Method for making and using IOL insertion apparatus
US6406739B1 (en) 2000-01-12 2002-06-18 Alcon Universal Ltd. Coating compositions and methods for reducing edge glare in implantable ophthalmic lenses
US6528602B1 (en) 1999-09-07 2003-03-04 Alcon Universal Ltd. Foldable ophthalmic and otorhinolaryngological device materials
US6730123B1 (en) 2000-06-22 2004-05-04 Proteus Vision, Llc Adjustable intraocular lens
US20040111151A1 (en) * 2002-12-05 2004-06-10 Advanced Medical Optics, Inc. Accommodating intraocular lens and method of manufacture thereof
US20040167555A1 (en) * 2001-07-23 2004-08-26 Fos Holding S.A. Device for separating the epithelium layer from the surface of the cornea of an eye
US20040220599A1 (en) * 2001-07-23 2004-11-04 Fos Holding S.A. Device for separating the epithelium layer from the surface of the cornea of an eye
US6932839B1 (en) * 2002-11-27 2005-08-23 William Kamerling Intraocular lens assembly and method
USRE38935E1 (en) 1998-10-29 2006-01-10 Advanced Medical Optics, Inc. Intraocular lenses made from polymeric compositions and monomers useful in said compositions
WO2006007303A2 (en) * 2004-06-18 2006-01-19 Medennium, Inc. Apparatus and method for implanting intraocular lens through a small incision
WO2006017835A2 (en) * 2004-08-06 2006-02-16 Sightrate B.V. Device for separating the epithelial layer from the surface of the cornea of eye
US20070265650A1 (en) * 2001-07-23 2007-11-15 Ioannis Pallikaris Device for separating the epithelial layer from the surface of the cornea of an eye
US7632431B2 (en) 2003-01-30 2009-12-15 Abbott Medical Optics Inc. Composite intraocular lens and method of manufacture thereof
US20100100177A1 (en) * 2008-10-20 2010-04-22 Advanced Medical Optics, Inc. Multifocal Intraocular Lens
US20100100178A1 (en) * 2008-10-20 2010-04-22 Advanced Medical Optics, Inc. Multifocal Intraocular Lens
US20100097569A1 (en) * 2008-10-20 2010-04-22 Advanced Medical Optics, Inc. Multifocal Intraocular Lens
WO2014111769A1 (en) 2013-01-15 2014-07-24 Medicem Ophthalmic (Cy) Limited Bioanalogic intraocular lens
US9011532B2 (en) 2009-06-26 2015-04-21 Abbott Medical Optics Inc. Accommodating intraocular lenses
US9039760B2 (en) 2006-12-29 2015-05-26 Abbott Medical Optics Inc. Pre-stressed haptic for accommodating intraocular lens
US9198752B2 (en) 2003-12-15 2015-12-01 Abbott Medical Optics Inc. Intraocular lens implant having posterior bendable optic
US9504560B2 (en) 2002-01-14 2016-11-29 Abbott Medical Optics Inc. Accommodating intraocular lens with outer support structure
US9603703B2 (en) 2009-08-03 2017-03-28 Abbott Medical Optics Inc. Intraocular lens and methods for providing accommodative vision
US9636213B2 (en) 2005-09-30 2017-05-02 Abbott Medical Optics Inc. Deformable intraocular lenses and lens systems
US9814570B2 (en) 1999-04-30 2017-11-14 Abbott Medical Optics Inc. Ophthalmic lens combinations
WO2017221068A1 (en) 2016-06-23 2017-12-28 Medicem Ophthalmic (Cy) Limited Light-adjustable hydrogel and bioanalogic intraocular lens
US9968441B2 (en) 2008-03-28 2018-05-15 Johnson & Johnson Surgical Vision, Inc. Intraocular lens having a haptic that includes a cap
US9987125B2 (en) 2012-05-02 2018-06-05 Johnson & Johnson Surgical Vision, Inc. Intraocular lens with shape changing capability to provide enhanced accomodation and visual acuity
US11707354B2 (en) 2017-09-11 2023-07-25 Amo Groningen B.V. Methods and apparatuses to increase intraocular lenses positional stability

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4834750A (en) * 1987-09-17 1989-05-30 Ioptex Research, Inc. Deformable-elastic intraocular lens
DE3927667A1 (en) * 1989-08-22 1991-02-28 Espe Stiftung USE OF PHOTOPOLYMERIZABLE MATERIALS AS INTROCULAR LENS FILLING MATERIAL IN THE FIGHT AGAINST CATARACT AND OTHER EYE DISEASES
FR2655270B1 (en) * 1989-12-05 1994-10-28 Ceskoslovenska Akademie Ved INTRAOCULAR LENS IN SHAPE MEMORY HYDROGEL.
US5269813A (en) * 1990-06-12 1993-12-14 Menicon Co., Ltd. Material for one-piece intraocular lenses
US5290892A (en) * 1990-11-07 1994-03-01 Nestle S.A. Flexible intraocular lenses made from high refractive index polymers
EP0514096A3 (en) * 1991-05-13 1993-03-31 Ioptex Research Inc. Deformable-elastic intraocular lens
FR2693649B1 (en) * 1992-07-16 1994-10-14 Corneal Flexible intraocular implant.
ATE181695T1 (en) * 1992-08-21 1999-07-15 Allergan Inc INTRAOCULAR LENSES AND METHOD FOR PRODUCING THE SAME
US5331073A (en) * 1992-11-09 1994-07-19 Allergan, Inc. Polymeric compositions and intraocular lenses made from same
US5653715A (en) * 1993-03-09 1997-08-05 Chiron Vision Corporation Apparatus for preparing an intraocular lens for insertion
US5549614A (en) * 1993-03-18 1996-08-27 Tunis; Scott W. Apparatus for folding flexible intraocular lenses
US5290293A (en) * 1993-06-21 1994-03-01 Alcon Surgical, Inc. Intraocular lens folder
US5468246A (en) * 1993-07-02 1995-11-21 Iovision, Inc. Intraocular lens injector
US5618316A (en) * 1993-12-14 1997-04-08 Hoffman; Allan S. Polyethylene oxide coated intraocular lens
AU1915595A (en) * 1994-02-09 1995-08-29 Kabi Pharmacia Ophthalmics, Inc. Rapid implantation of shape transformable optical lenses
US5454818A (en) * 1994-07-26 1995-10-03 Alcon Laboratories, Inc. Intraocular lens folder
US5611968A (en) * 1994-08-16 1997-03-18 Allergan Method of making intraocular lenses
US5507804A (en) * 1994-11-16 1996-04-16 Alcon Laboratories, Inc. Cross-linked polyethylene oxide coatings to improve the biocompatibility of implantable medical devices
US5556400A (en) * 1994-12-27 1996-09-17 Tunis; Scott W. Methods of preparing and inserting flexible intraocular lenses and a configuration for flexible intraocular lenses
RU2074673C1 (en) * 1995-06-01 1997-03-10 Межотраслевой научно-технический комплекс "Микрохирургия глаза" Elastic artificial crystalline lens and method for manufacturing same
WO1996040303A1 (en) * 1995-06-07 1996-12-19 Alcon Laboratories, Inc. Improved high refractive index ophthalmic lens materials
US5716403A (en) * 1995-12-06 1998-02-10 Alcon Laboratories, Inc. Single piece foldable intraocular lens
US6132462A (en) * 1995-12-22 2000-10-17 Santen Pharmaceutical Co., Ltd. Copolymers formed from three components and intraocular lenses made thereof
US5922821A (en) * 1996-08-09 1999-07-13 Alcon Laboratories, Inc. Ophthalmic lens polymers
US5855604A (en) * 1996-12-09 1999-01-05 Microoptix, Llc Method and apparatus for adjusting corneal curvature using a solid filled corneal ring
US5876439A (en) * 1996-12-09 1999-03-02 Micooptix, Llc Method and appartus for adjusting corneal curvature using a fluid-filled corneal ring
US5733334A (en) * 1996-12-09 1998-03-31 Microoptix Method and apparatus for adjusting corneal curvature
US5702400A (en) 1996-12-11 1997-12-30 Alcon Laboratories, Inc. Intraocular lens folder
US5919230A (en) * 1997-03-18 1999-07-06 Sambursky; Daniel Louis. Intraocular lens implant and method of making same
US6228114B1 (en) 1997-04-01 2001-05-08 Joseph Y. Lee Adjustable corneal ring
JPH11385A (en) * 1997-04-17 1999-01-06 Menicon Co Ltd Sterilizing method for intraocular lens
US6231583B1 (en) 1997-07-09 2001-05-15 Joseph Y. Lee Corneal circular channel dissecting device
US6786928B2 (en) 1997-08-20 2004-09-07 Thinoptx, Inc. Small incision lens
US6488707B1 (en) * 1997-08-20 2002-12-03 Thinoptx, Inc. Method of implanting a deformable intraocular corrective lens
US6800091B2 (en) 1997-08-20 2004-10-05 Thinoptx, Inc. Method of using a small incision lens
US6096077A (en) * 1997-08-20 2000-08-01 Thinoptx, Inc. Deformable intraocular corrective lens
NZ336670A (en) * 1997-12-02 2001-02-23 Hoya Healthcare Corp Intraocular lens with soft copolymer optic portion and hard polymer haptic portion
US6206919B1 (en) 1998-01-14 2001-03-27 Joseph Y. Lee Method and apparatus to correct refractive errors using adjustable corneal arcuate segments
BR9909618A (en) * 1998-04-15 2000-12-12 Alcon Lab Inc High refractive index ophthalmic device materials prepared using a post-polymerization crosslinking process
US6313187B2 (en) 1998-04-15 2001-11-06 Alcon Manufacturing, Ltd. High refractive index ophthalmic device materials prepared using a post-polymerization cross-linking method
US6517577B1 (en) * 1998-05-28 2003-02-11 Thinoptx, Inc. Crossed haptics for intraocular lenses
US6201036B1 (en) * 1998-07-21 2001-03-13 Mezhoiraslevoi Nauchno-Tekhnichesky Komplex “Mikrokhirurgia Glaza” Light-curable polymer material, method for making an elastic intraocular lens, and an elastic intraocular lens
AU760960B2 (en) * 1998-10-29 2003-05-22 Advanced Medical Optics, Inc. Intraocular lenses made from polymeric compositions
US6241766B1 (en) 1998-10-29 2001-06-05 Allergan Sales, Inc. Intraocular lenses made from polymeric compositions
DE69915114T2 (en) * 1998-12-11 2004-09-09 Biocompatibles Uk Ltd., Farnham CROSSLINKED POLYMERS AND REFRACTOR DEVICE MOLDED FROM THESE
EP1035142A1 (en) * 1999-03-09 2000-09-13 Nidek Co., Ltd. Acrylic copolymer materials suitable for ophthalmic devices
US6281319B1 (en) 1999-04-12 2001-08-28 Surgidev Corporation Water plasticized high refractive index polymer for ophthalmic applications
US8247511B2 (en) * 1999-04-12 2012-08-21 Advanced Vision Science, Inc. Water plasticized high refractive index polymer for ophthalmic applications
US6271281B1 (en) 1999-08-26 2001-08-07 Medennium, Inc. Homopolymers containing stable elasticity inducing crosslinkers and ocular implants made therefrom
AUPQ765200A0 (en) * 2000-05-19 2000-06-15 Oversby Pty Ltd Intraocular lens implants
US6679605B2 (en) 2000-05-22 2004-01-20 Medennium, Inc. Crystalline polymeric compositions for ophthalmic devices
US20020022882A1 (en) * 2000-08-17 2002-02-21 Morgan Courtney Flem Rollable intraocular lens having reduced thickness
US7060095B2 (en) * 2001-05-08 2006-06-13 Unisearch Limited Supplementary endo-capsular lens and method of implantation
US6737448B2 (en) * 2002-06-03 2004-05-18 Staar Surgical Company High refractive index, optically clear and soft hydrophobic acrylamide copolymers
US6939486B2 (en) * 2002-06-25 2005-09-06 Bausch & Lomb Incorporated Apparatus and method for making intraocular lenses
JP4404533B2 (en) * 2002-08-30 2010-01-27 株式会社ニデック Manufacturing method of intraocular lens and intraocular lens obtained by the method
US20040056371A1 (en) * 2002-09-25 2004-03-25 Medennium, Inc. Method of manufacturing ophthalmic lenses made from hydrophobic acrylic polymers
US7303582B2 (en) * 2003-03-21 2007-12-04 Advanced Medical Optics, Inc. Foldable angle-fixated intraocular lens
US7354980B1 (en) 2004-03-12 2008-04-08 Key Medical Technologies, Inc. High refractive index polymers for ophthalmic applications
US7247689B2 (en) * 2004-05-28 2007-07-24 Advanced Medical Optics, Inc. Biocompatible polymeric compositions for use in making anterior chamber intraocular lenses
US7446157B2 (en) 2004-12-07 2008-11-04 Key Medical Technologies, Inc. Nanohybrid polymers for ophthalmic applications
US8377125B2 (en) 2006-04-05 2013-02-19 Anew Optics, Inc. Intraocular lens with accommodation
US20070282438A1 (en) * 2006-05-31 2007-12-06 Xin Hong Intraocular lenses with enhanced off-axis visual performance
TW200816966A (en) * 2006-07-21 2008-04-16 Alcon Mfg Ltd Low-tack ophthalmic and otorhinolaryngological device materials
US7714039B2 (en) * 2006-07-21 2010-05-11 Alcon, Inc. Low-tack ophthalmic and otorhinolaryngological device materials
US8058323B2 (en) * 2006-07-21 2011-11-15 Novartis Ag Low-tack ophthalmic and otorhinolaryngological device materials
TWI399228B (en) * 2006-07-21 2013-06-21 Alcon Inc Low-tack ophthalmic and otorhinolaryngological device materials
JP2008110625A (en) * 2006-10-27 2008-05-15 Toyo Tire & Rubber Co Ltd Pneumatic tire
CN101678149B (en) * 2007-02-21 2013-07-17 力景公司 Polymeric materials suitable for ophthalmic devices and methods of manufacture
ES2365290T3 (en) * 2007-07-25 2011-09-28 Alcon, Inc. MATERIALS FOR HIGH INDOOR REFRACTION OPTIONAL DEVICE.
US20090088842A1 (en) * 2007-09-27 2009-04-02 Drew Morgan Intraocular Lens
US8480734B2 (en) 2007-12-27 2013-07-09 Anew Optics, Inc. Intraocular lens with accommodation
US20090292356A1 (en) * 2008-05-22 2009-11-26 Michael Hamlin Reduced profile intraocular lens
RU2011119513A (en) * 2008-10-15 2012-11-27 Алькон, Инк. ACCOMMODATING IN-EYE LENS
US10010405B2 (en) 2008-11-26 2018-07-03 Anew Aol Technologies, Inc. Haptic devices for intraocular lens
CN102292051A (en) 2008-11-26 2011-12-21 安纽光学公司 Haptic devices for intraocular lens
US8222360B2 (en) 2009-02-13 2012-07-17 Visiogen, Inc. Copolymers for intraocular lens systems
US20110191086A1 (en) * 2010-02-04 2011-08-04 Anew Optics, Inc. Model of accommodative intraocular lens
WO2012074076A1 (en) * 2010-12-01 2012-06-07 日産化学工業株式会社 Fluorine-containing hyperbranched polymer, and photo-sensitive composition containing same
TWI517861B (en) 2011-02-08 2016-01-21 諾華公司 Low-tack, hydrophobic ophthalmic device materials
TWI513768B (en) 2011-06-01 2015-12-21 Novartis Ag Hydrophobic acrylic intraocular lens materials
TWI551646B (en) 2011-06-03 2016-10-01 諾華公司 Hydrophobic acrylic intraocular lens materials
US9855136B2 (en) 2012-01-19 2018-01-02 Eyebright Medical Technology (Beijing) Co., Ltd. Posterior chamber intraocular lens
WO2015084788A1 (en) 2013-12-04 2015-06-11 Novartis Ag Soft acrylic materials with high refractive index and minimized glistening
EP3191022B1 (en) 2014-09-09 2022-05-04 Staar Surgical Company Ophthalmic implants with extended depth of field and enhanced distance visual acuity
JP6371480B2 (en) 2014-12-16 2018-08-08 ノバルティス アーゲー Low water content acrylate-acrylamide copolymers for ophthalmic appliances
CN106999628A (en) 2014-12-16 2017-08-01 诺华股份有限公司 Hydrophobic acrylic acid's ester acrylamide copolymer for Ophthalmoligic instrument
WO2016133656A1 (en) 2015-02-16 2016-08-25 Novartis Ag Wet-pack intraocular lens materials with high refractive index
JP6953423B2 (en) 2016-03-09 2021-10-27 スター サージカル カンパニー Ophthalmic implants with extended depth of field and improved distant vision
CN114532976A (en) 2016-05-31 2022-05-27 酷拉公司 Implantable intraocular pressure sensor and method of use
RU2728693C1 (en) 2017-06-05 2020-07-31 Алькон Инк. Materials for intraocular lens with high refraction index and high abbe number
US11684703B2 (en) 2018-02-20 2023-06-27 Qura, Inc. Coatings for implantable devices
CA3096256A1 (en) 2018-04-06 2019-10-10 Amo Development, Llc Methods and systems for changing a refractive property of an implantable intraocular lens
US10774164B2 (en) 2018-08-17 2020-09-15 Staar Surgical Company Polymeric composition exhibiting nanogradient of refractive index
KR20220036946A (en) 2019-06-27 2022-03-23 레이어바이오 인크. Ocular Device Delivery Methods and Systems
CN113916929B (en) * 2021-09-17 2023-04-07 东方电气集团东方电机有限公司 Method for evaluating main insulation curing degree of generator stator bar
US20230149153A1 (en) * 2021-11-16 2023-05-18 Joon Bu Park Negative poisson`s ratio materials for intraocular lenses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980001058A1 (en) * 1978-11-24 1980-05-29 Esselte Pendaflex Corp Expanding card file
WO1981000570A1 (en) * 1979-08-20 1981-03-05 Retina Foundation Hydrogel implant article and method
US4668446A (en) * 1985-09-27 1987-05-26 Cilco, Inc. Process for making soft contact and intraocular lenses with an esterifiable carboxyl-containing polymer
US4731079A (en) * 1986-11-26 1988-03-15 Kingston Technologies, Inc. Intraocular lenses
EP0308130A2 (en) * 1987-09-17 1989-03-22 Ioptex Research Inc. Deformable-elastic intraocular lens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436887A (en) * 1981-11-12 1984-03-13 Bausch & Lomb Incorporated N-Vinyl lactam based biomedical devices
EP0161764B1 (en) * 1984-04-11 1989-01-11 Pharmacia Ab Intraocular implant
JPS6152873A (en) * 1984-08-20 1986-03-15 オプチカル ラジエ−シヨン コ−ポレイシヨン Production of intraocular lens absorbing ultraviolet rays
JPS6214860A (en) * 1985-07-12 1987-01-23 東洋コンタクトレンズ株式会社 Medical material
JPS6297559A (en) * 1985-10-23 1987-05-07 株式会社メニコン Intraocular lens material

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980001058A1 (en) * 1978-11-24 1980-05-29 Esselte Pendaflex Corp Expanding card file
WO1981000570A1 (en) * 1979-08-20 1981-03-05 Retina Foundation Hydrogel implant article and method
US4668446A (en) * 1985-09-27 1987-05-26 Cilco, Inc. Process for making soft contact and intraocular lenses with an esterifiable carboxyl-containing polymer
US4731079A (en) * 1986-11-26 1988-03-15 Kingston Technologies, Inc. Intraocular lenses
EP0269288A1 (en) * 1986-11-26 1988-06-01 Kingston Technologies, Inc. Intraocular lenses
EP0308130A2 (en) * 1987-09-17 1989-03-22 Ioptex Research Inc. Deformable-elastic intraocular lens

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6283975B1 (en) * 1996-07-10 2001-09-04 Allergan Sales, Inc. IOL insertion apparatus and method for making and using same
US6398788B1 (en) * 1996-07-10 2002-06-04 Allergan Method for making and using IOL insertion apparatus
USRE38935E1 (en) 1998-10-29 2006-01-10 Advanced Medical Optics, Inc. Intraocular lenses made from polymeric compositions and monomers useful in said compositions
US6245106B1 (en) 1998-10-29 2001-06-12 Allergan Sales, Inc. Intraocular lenses made from polymeric compositions and monomers useful in said compositions
US9814570B2 (en) 1999-04-30 2017-11-14 Abbott Medical Optics Inc. Ophthalmic lens combinations
US6528602B1 (en) 1999-09-07 2003-03-04 Alcon Universal Ltd. Foldable ophthalmic and otorhinolaryngological device materials
US6653422B2 (en) 1999-09-07 2003-11-25 Alcon Universal Ltd. Foldable ophthalmic and otorhinolaryngological device materials
US6406739B1 (en) 2000-01-12 2002-06-18 Alcon Universal Ltd. Coating compositions and methods for reducing edge glare in implantable ophthalmic lenses
US6632887B2 (en) 2000-01-12 2003-10-14 Alcon Universal Ltd. Coating compositions and methods for reducing edge glare in implantable ophthalmic lenses
US6730123B1 (en) 2000-06-22 2004-05-04 Proteus Vision, Llc Adjustable intraocular lens
US20040167555A1 (en) * 2001-07-23 2004-08-26 Fos Holding S.A. Device for separating the epithelium layer from the surface of the cornea of an eye
US20040220599A1 (en) * 2001-07-23 2004-11-04 Fos Holding S.A. Device for separating the epithelium layer from the surface of the cornea of an eye
US20070265650A1 (en) * 2001-07-23 2007-11-15 Ioannis Pallikaris Device for separating the epithelial layer from the surface of the cornea of an eye
US7708750B2 (en) 2001-07-23 2010-05-04 Fos Holdings S.A. Device for separating the epithelium layer from the surface of the cornea of an eye
US9504560B2 (en) 2002-01-14 2016-11-29 Abbott Medical Optics Inc. Accommodating intraocular lens with outer support structure
US6932839B1 (en) * 2002-11-27 2005-08-23 William Kamerling Intraocular lens assembly and method
US7662180B2 (en) * 2002-12-05 2010-02-16 Abbott Medical Optics Inc. Accommodating intraocular lens and method of manufacture thereof
US10206773B2 (en) 2002-12-05 2019-02-19 Johnson & Johnson Surgical Vision, Inc. Accommodating intraocular lens and method of manufacture thereof
US20040111151A1 (en) * 2002-12-05 2004-06-10 Advanced Medical Optics, Inc. Accommodating intraocular lens and method of manufacture thereof
US9271830B2 (en) 2002-12-05 2016-03-01 Abbott Medical Optics Inc. Accommodating intraocular lens and method of manufacture thereof
US20100217387A1 (en) * 2002-12-05 2010-08-26 Abbott Medical Optics Inc. Accommodating intraocular lens and method of manufacture thereof
US7632431B2 (en) 2003-01-30 2009-12-15 Abbott Medical Optics Inc. Composite intraocular lens and method of manufacture thereof
US9198752B2 (en) 2003-12-15 2015-12-01 Abbott Medical Optics Inc. Intraocular lens implant having posterior bendable optic
WO2006007303A3 (en) * 2004-06-18 2006-08-24 Medennium Inc Apparatus and method for implanting intraocular lens through a small incision
WO2006007303A2 (en) * 2004-06-18 2006-01-19 Medennium, Inc. Apparatus and method for implanting intraocular lens through a small incision
WO2006017835A2 (en) * 2004-08-06 2006-02-16 Sightrate B.V. Device for separating the epithelial layer from the surface of the cornea of eye
WO2006017835A3 (en) * 2004-08-06 2007-11-08 Sightrate B V Device for separating the epithelial layer from the surface of the cornea of eye
US9636213B2 (en) 2005-09-30 2017-05-02 Abbott Medical Optics Inc. Deformable intraocular lenses and lens systems
US9039760B2 (en) 2006-12-29 2015-05-26 Abbott Medical Optics Inc. Pre-stressed haptic for accommodating intraocular lens
US9968441B2 (en) 2008-03-28 2018-05-15 Johnson & Johnson Surgical Vision, Inc. Intraocular lens having a haptic that includes a cap
US8292953B2 (en) 2008-10-20 2012-10-23 Amo Groningen B.V. Multifocal intraocular lens
US20100097569A1 (en) * 2008-10-20 2010-04-22 Advanced Medical Optics, Inc. Multifocal Intraocular Lens
US8734511B2 (en) 2008-10-20 2014-05-27 Amo Groningen, B.V. Multifocal intraocular lens
US9622856B2 (en) 2008-10-20 2017-04-18 Abbott Medical Optics Inc. Multifocal intraocular lens
US10327887B2 (en) 2008-10-20 2019-06-25 Johnson & Johnson Surgical Vision, Inc. Multifocal intraocular lens
US20100100178A1 (en) * 2008-10-20 2010-04-22 Advanced Medical Optics, Inc. Multifocal Intraocular Lens
US20100100177A1 (en) * 2008-10-20 2010-04-22 Advanced Medical Optics, Inc. Multifocal Intraocular Lens
US8771348B2 (en) 2008-10-20 2014-07-08 Abbott Medical Optics Inc. Multifocal intraocular lens
US10052194B2 (en) 2009-06-26 2018-08-21 Johnson & Johnson Surgical Vision, Inc. Accommodating intraocular lenses
US9011532B2 (en) 2009-06-26 2015-04-21 Abbott Medical Optics Inc. Accommodating intraocular lenses
US9603703B2 (en) 2009-08-03 2017-03-28 Abbott Medical Optics Inc. Intraocular lens and methods for providing accommodative vision
US10105215B2 (en) 2009-08-03 2018-10-23 Johnson & Johnson Surgical Vision, Inc. Intraocular lens and methods for providing accommodative vision
US9987125B2 (en) 2012-05-02 2018-06-05 Johnson & Johnson Surgical Vision, Inc. Intraocular lens with shape changing capability to provide enhanced accomodation and visual acuity
WO2014111769A1 (en) 2013-01-15 2014-07-24 Medicem Ophthalmic (Cy) Limited Bioanalogic intraocular lens
WO2017221068A1 (en) 2016-06-23 2017-12-28 Medicem Ophthalmic (Cy) Limited Light-adjustable hydrogel and bioanalogic intraocular lens
US11707354B2 (en) 2017-09-11 2023-07-25 Amo Groningen B.V. Methods and apparatuses to increase intraocular lenses positional stability

Also Published As

Publication number Publication date
CA1340128C (en) 1998-11-17
EP0308130A2 (en) 1989-03-22
JPH01158949A (en) 1989-06-22
CA1330474C (en) 1994-07-05
EP0308130A3 (en) 1989-12-27
DE3870779D1 (en) 1992-06-11
JP2930306B2 (en) 1999-08-03
CA1340128E (en) 1998-11-17
EP0308130B1 (en) 1992-05-06
US4834750A (en) 1989-05-30

Similar Documents

Publication Publication Date Title
USRE36150E (en) Deformable-elastic intraocular lens
JP5096793B2 (en) Polymer composition and ophthalmic lens body
EP1289740B1 (en) Crystalline polymeric compositions for ophthalmic devices
US7247689B2 (en) Biocompatible polymeric compositions for use in making anterior chamber intraocular lenses
US6780899B2 (en) Homopolymers containing stable elasticity inducing crosslinkers and ocular implants made therefrom
US5290892A (en) Flexible intraocular lenses made from high refractive index polymers
AU2005336100B2 (en) Biocompatible polymeric compositions for use in making anterior chamber intraocular lenses
EP0485197A1 (en) Polymers and their use for ophthalmic lenses
US20010005743A1 (en) Intraocular lenses made from polymeric compositions
US5507805A (en) Intraocular lens and method of retaining in place
US20110245442A1 (en) Hydrophobic acrylic polymer material for an intraocular lens having enhanced flexibility due to the use of a transfer agent
EP1816985B1 (en) Biocompatible polymeric compositions for use in making posterior chamber intraocular lenses
AU661306B2 (en) Deformable-elastic intraocular lens
JP2005531363A (en) Surface modified intraocular lens
EP0034174B1 (en) Hydrogel implant article and method
WO2000057213A1 (en) Polymeric material compositions and intraocular lenses made from same
RU2128025C1 (en) Artificial crystalline lens of eye

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALLERGAN, TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALLERGAN, INC.;REEL/FRAME:008128/0097

Effective date: 19960117

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: BANK OF AMERICA, N.A., NEW YORK

Free format text: SECURITY AGREEMENT;ASSIGNORS:ADVANCED MEDICAL OPTICS, INC.;AMO HOLDINGS, LLC;REEL/FRAME:013203/0039

Effective date: 20020621

AS Assignment

Owner name: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT, NO

Free format text: SECURITY AGREEMENT;ASSIGNOR:ADVANCED MEDICAL OPTICS, INC.;REEL/FRAME:016386/0001

Effective date: 20040625

AS Assignment

Owner name: ADVANCED MEDICAL OPTICS, INC., CALIFORNIA

Free format text: RELEASE OF SECURITY INTEREST AT REEL/FRAME NO. 16386/0001;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:019116/0124

Effective date: 20070402

Owner name: AMO HOLDINGS, INC. (FORMERLY KNOWN AS AMO HOLDINGS

Free format text: RELEASE OF SECURITY INTEREST AT REEL/FRAME NO. 13203/0039;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:019111/0348

Effective date: 20070402

Owner name: ADVANCED MEDICAL OPTICS, INC., CALIFORNIA

Free format text: RELEASE OF SECURITY INTEREST AT REEL/FRAME NO. 13203/0039;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:019111/0348

Effective date: 20070402

AS Assignment

Owner name: AMO PUERTO RICO MANUFACTURING, INC., PUERTO RICO

Free format text: ASSET PURCHASE AGREEMENT;ASSIGNOR:AMO PUERTO RICO, INC.;REEL/FRAME:023032/0073

Effective date: 20020628